Whistleblower Lawsuit Ends in $25M Price-Fixing Settlement
Drugmaker allegedly conspired with competitors to manipulate drug prices A whistleblower has played a pivotal role in exposing alleged price-fixing by generic drugmaker Glenmark Pharmaceuticals Inc. USA, resulting in a $25 million False Claims Act settlement. Glenmark—the American branch of Glenmark Pharmaceuticals (NSE: Glenmark) based in Mumbai, India—was accused of conspiring with competing generic pharmaceutical manufacturers to fix the price